| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10011026 | Journal of the American Academy of Dermatology | 2005 | 7 Pages |
Abstract
Rituximab therapy is a well-tolerated and effective treatment for primary CBCL. In comparison to intravenous administration, intralesional application of the drug allows the use of lower dosages. Intralesional therapy with rituximab deserves further investigation and comparison to systemic administration of the drug in controlled multicenter studies.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Regina MD, Ingrid H. MD, Iris MD, Helmut MD, Lorenzo MD,